Cytokinetics, Incorporated (CYTK)
NASDAQ$44.4
Market Cap
$5.26B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
550 of 925
Rank in Industry
320 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CYTK Insider Trading Activity
CYTK Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $24,181,889 | 60 | 100 |
Related Transactions
| Bhanji Muna | director | 0 | $0 | 1 | $104,140 | $-104,140 |
| Harrington Robert Arthur | director | 0 | $0 | 3 | $128,918 | $-128,918 |
| WIERENGA WENDALL | director | 0 | $0 | 3 | $305,786 | $-305,786 |
| Wong Robert | VP, Chief Accounting Officer | 0 | $0 | 1 | $635,978 | $-635,978 |
| HENDERSON JOHN T | director | 0 | $0 | 2 | $771,419 | $-771,419 |
| Callos Andrew | EVP, Chief Commercial Officer | 0 | $0 | 3 | $1.36M | $-1.36M |
| PARSHALL B LYNNE | director | 0 | $0 | 8 | $2.19M | $-2.19M |
| Blum Robert I | President & CEO | 0 | $0 | 16 | $8.91M | $-8.91M |
| Malik Fady Ibraham | EVP Research & Development | 0 | $0 | 23 | $9.77M | $-9.77M |
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase …
Insider Activity of Cytokinetics, Incorporated
Over the last 12 months, insiders at Cytokinetics, Incorporated have bought $0 and sold $24.18M worth of Cytokinetics, Incorporated stock.
On average, over the past 5 years, insiders at Cytokinetics, Incorporated have bought $0 and sold $19.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 118,413 shares for transaction amount of $1.13M was made by BVF PARTNERS L P/IL (10 percent owner) on 2019‑12‑11.
List of Insider Buy and Sell Transactions, Cytokinetics, Incorporated
| 2025-03-13 | Sale | Callos Andrew | EVP, Chief Commercial Officer | 26,771 0.0222% | $43.62 | $1.17M | +1.79% | |
| 2025-03-06 | Sale | Blum Robert I | President & CEO | 16,970 0.0145% | $43.44 | $737,177 | +1.66% | |
| 2025-03-06 | Sale | Malik Fady Ibraham | EVP Research & Development | 8,228 0.007% | $43.27 | $356,026 | +1.66% | |
| 2025-03-06 | Sale | Callos Andrew | EVP, Chief Commercial Officer | 3,341 0.0028% | $43.27 | $144,565 | +1.66% | |
| 2025-03-05 | Sale | Blum Robert I | President & CEO | 25,000 0.021% | $43.23 | $1.08M | -0.41% | |
| 2025-03-04 | Sale | Malik Fady Ibraham | EVP Research & Development | 2,000 0.0016% | $42.50 | $85,000 | +0.46% | |
| 2025-03-04 | Sale | Harrington Robert Arthur | director | 900 0.0007% | $42.50 | $38,250 | +0.46% | |
| 2025-03-03 | Sale | Blum Robert I | President & CEO | 8,743 0.0074% | $42.88 | $374,900 | +2.10% | |
| 2025-03-03 | Sale | Malik Fady Ibraham | EVP Research & Development | 2,449 0.0021% | $42.88 | $105,013 | +2.10% | |
| 2025-03-03 | Sale | Callos Andrew | EVP, Chief Commercial Officer | 1,114 0.0009% | $42.88 | $47,768 | +2.10% | |
| 2025-02-18 | Sale | Malik Fady Ibraham | EVP Research & Development | 2,000 0.0017% | $45.98 | $91,960 | -4.36% | |
| 2025-02-04 | Sale | Malik Fady Ibraham | EVP Research & Development | 2,000 0.0017% | $48.06 | $96,120 | -9.76% | |
| 2025-01-21 | Sale | Malik Fady Ibraham | EVP Research & Development | 2,000 0.0017% | $45.92 | $91,840 | +1.48% | |
| 2025-01-07 | Sale | Malik Fady Ibraham | EVP Research & Development | 2,000 0.0017% | $49.32 | $98,640 | -3.95% | |
| 2024-12-16 | Sale | WIERENGA WENDALL | director | 742 0.0006% | $48.61 | $36,069 | -4.26% | |
| 2024-12-11 | Sale | HENDERSON JOHN T | director | 1,780 0.0015% | $50.42 | $89,748 | -7.22% | |
| 2024-12-10 | Sale | Malik Fady Ibraham | EVP Research & Development | 7,300 0.0062% | $50.64 | $369,639 | -6.83% | |
| 2024-12-02 | Sale | Blum Robert I | President & CEO | 5,000 0.0043% | $50.76 | $253,800 | -6.45% | |
| 2024-11-26 | Sale | Malik Fady Ibraham | EVP Research & Development | 7,300 0.006% | $50.16 | $366,181 | -8.79% | |
| 2024-11-25 | Sale | WIERENGA WENDALL | director | 742 0.0006% | $50.00 | $37,100 | -5.24% |
Total: 538
*Gray background shows transactions not older than one year
Insider Historical Profitability
18.62%
| HENDERSON JOHN T | director | 38461 0.0325% | $1.71M | 1 | 11 | +75.35% |
| SCHMERTZLER MICHAEL | director | 4340923 3.666% | $192.74M | 1 | 8 | +68.65% |
| Eastern Capital LTD | 10 percent owner | 2883845 2.4355% | $128.04M | 1 | 0 | |
| DOW STEPHEN M | director | 1421052 1.2001% | $63.09M | 9 | 1 | <0.0001% |
| BVF PARTNERS L P/IL | 463244 0.3912% | $20.57M | 2 | 2 | +74.11% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$159,914,414 | 243 | 18.52% | $5.79B | |
$211,610,344 | 91 | 38.45% | $7.13B | |
$52,263,649 | 70 | 1.18% | $4.23B | |
$415,105,240 | 19 | -14.04% | $6.15B | |
Cytokinetics, Incorporated (CYTK) | $11,859,102 | 17 | 18.62% | $5.26B |
CYTK Institutional Investors: Active Positions
| Increased Positions | 172 | +41.85% | 13M | +9.44% |
| Decreased Positions | 183 | -44.53% | 15M | -11.46% |
| New Positions | 50 | New | 3M | New |
| Sold Out Positions | 52 | Sold Out | 4M | Sold Out |
| Total Postitions | 400 | -2.68% | 132M | -2.02% |
CYTK Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $711,591.00 | 13.11% | 15.47M | +216,539 | +1.42% | 2024-12-31 |
| Vanguard Group Inc | $548,128.00 | 10.1% | 11.92M | +154,216 | +1.31% | 2024-12-31 |
| Fmr Llc | $496,556.00 | 9.15% | 10.79M | -1M | -10.74% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $494,598.00 | 9.11% | 10.75M | +1M | +10.96% | 2024-12-31 |
| Wellington Management Group Llp | $362,880.00 | 6.69% | 7.89M | +113,727 | +1.46% | 2024-12-31 |
| State Street Corp | $283,698.00 | 5.23% | 6.17M | -290,984 | -4.51% | 2024-12-31 |
| Geode Capital Management, Llc | $130,702.00 | 2.41% | 2.84M | -7,246 | -0.25% | 2024-12-31 |
| Rtw Investments, Lp | $125,173.00 | 2.31% | 2.72M | 0 | 0% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $120,754.00 | 2.23% | 2.63M | -539,864 | -17.06% | 2024-12-31 |
| Deep Track Capital, Lp | $115,000.00 | 2.12% | 2.5M | +2M | +296.88% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.